Ibandronic acid
Also known as: Ibandronate sodium
Active ingredient description
Ibandronic acid belongs to the bisphosphonate group of compounds which act specifically on bone. Their selective action on bone tissue is based on the high affinity of bisphosphonates for bone mineral. Bisphosphonates act by inhibiting osteoclast activity, although the precise mechanism is still not clear. In vivo, ibandronic acid prevents experimentally-induced bone destruction caused by cessation of gonadal function, retinoids, tumours or tumour extracts.
Medicine classification
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Product monographs
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Medicines
Ibandronic acid is the active ingredient of these drugs:
Spain
Ecuador
Brazil
Germany
Estonia Lithuania
Ecuador
South Africa
Australia Austria Ecuador Estonia France
Ecuador
Estonia Ireland Lithuania Poland
Ecuador
South Africa United States
Hong Kong
Germany
South Africa
Austria Brazil Cyprus Ecuador Estonia
Finland
Ecuador
Ecuador
Estonia
Ecuador
Austria Cyprus Estonia Ireland Lithuania
Ecuador
Brazil
Brazil
Ecuador
Ecuador
Ecuador
Poland
Austria Estonia Poland
Estonia
Poland
Lithuania Poland
Brazil
Ecuador Estonia Lithuania Poland
Brazil
Ecuador
Brazil
Austria
South Africa
United Kingdom
Ecuador
Ecuador
Brazil
Ibandronic acid is also found within below combination drugs: